Daymark Wealth Partners’s AstraZeneca AZN Stock Holding History

Daymark Wealth Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Buy	+11,737	New	+$2.21M	0.05%	238
2024 Q4	–	Sell	-2,962	Closed	-$462K	–	496
2024 Q3	$462K	Buy	2,962 +37	+1%	+$5.97K	0.02%	347
2024 Q2	$456K	Buy	2,925 +186	+7%	+$28K	0.02%	334
2024 Q1	$371K	Sell	2,739 -332	-11%	-$44K	0.02%	308
2023 Q4	$414K	Buy	3,071 +381	+14%	+$49.5K	0.03%	276
2023 Q3	$364K	Sell	2,690 -118	-4%	-$16.1K	0.03%	274
2023 Q2	$402K	Buy	+2,808	New	+$413K	0.03%	258

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Daymark Wealth Partners's AZN Position: Q2 2026 in Review

Daymark Wealth Partners opened a new position in AstraZeneca (AZN) in Q2 2026: 11,737 shares worth $2.23M. The stake represents 0.05% of the portfolio and ranks #238 among its holdings. This is a return to the name: Daymark Wealth Partners previously reported a position in AZN as recently as Q3 2024.

Daymark Wealth Partners first reported a position in AZN in Q2 2023 and has held it in 7 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Daymark Wealth Partners held 11,737 shares of AstraZeneca worth $2.23M as of Q2 2026.
AstraZeneca was a new Daymark Wealth Partners position in Q2 2026.
AstraZeneca made up 0.05% of Daymark Wealth Partners's portfolio in Q2 2026, its #238 holding.
Daymark Wealth Partners first reported a position in AstraZeneca in Q2 2023 and has held it in 7 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.